

INNOVATORS IN BREAST CANCER

Aula Magna Campus Perrone – UPO, Novara

10-11 September 2021

Conference Chairs: *Alessandra Gennari, Marco Krengli*
Directors

Alessandra Gennari, Marco Krengli, Filippo Montemurro

Friday, 10th September

9.00 Registration & Welcome Coffee

9.20 Welcome to the IBC Meeting 2021

GianCarlo Avanzi, Dean University of Piemonte Orientale

Gianfranco Zulian, General Manager, AOU Maggiore della Carità, Novara

9.30 Opening of the 3rd IBC Meeting 2021

Alessandra Gennari, Marco Krengli, Filippo Montemurro

Chairs: *Paolo Pronzato, TBD*

- COVID-19 and cancer prognosis - *David Pinato*

- COVID-19: Impact on Breast Cancer - *Livia Giordano*

Chair *Giancarlo Avanzi*

Lecture Psychologic Distress during the COVID-19 pandemic - *Gabriella Pravettoni*

10.20 How to personalize loco-regional treatment based on the response to neoadjuvant systemic therapy?

Chairs: *Marco Krengli, Pierfranco Conte*

- The role of systemic therapy and escalation - *Valentina Guarneri*

- Strategies for Targeted Axillary Dissection and Breast Surgery - *Giovanni Corso*

10.55 Coffee Break

- RT strategy, including indication and volumes (nodes) - *Yazid Belkacemi*

- RT schedule (technique, including dose and fractionation) - *Cynthia Aristei*

- RT combination schedules with new drugs - *Pierfrancesco Franco*

Discussion



Sistema Qualità **ISO 9001**
Progettazione e Erogazione ECM

12.30 Meeting AMGEN NO CME

Chairs *Alessandra Gennari, Marco Krengli*

- Denosumab in early-stage breast cancer - *Michael Gnant*
- Treatment of metastatic bone lesions - *Daniele Santini*

13.00 Lunch

14.00 Adjuvant therapy in EBC: escalating and de-escalating schedules

Chairs: *Fabio Puglisi, Michelino De Laurentiis*

- De-escalating and escalating care for early stage ER+/HER2- disease - *Fatima Cardoso*
- De-escalating and escalating care for early stage HER2+ disease - *Pierfranco Conte*
- Guided discussion and vote - *Giampaolo Bianchini*

15.00 Pathology Session

Chairs: *Giuseppe Viale, Renzo Boldorini*

- Questions for the pathologist by a clinicians - *Carmen Criscitello*
- Re-testing of predictive biomarkers on surgical specimens is clinically relevant? *Isabella Castellano*
- PD-L1 and PI3K: when, where, how? - *Caterina Marchiò*

Discussion

15.50 Molecular Biology

Chairs: *Marianna Nuti, Antonio Sica*

- Novel RNA-based approaches towards precision medicine in HR+/HER2- breast cancer - *Aleix Prat*
- Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: towards an Optimized Treatment Approach - *Christos Sotiriou*
- Spatial distribution of the immune infiltrate as a putative predictor of recurrence type in triple negative breast cancer - *Nina Radosevich*
- Extracellular Vesicles as Signaling Mediators and Disease Biomarkers - *Paola Lanuti*

Discussion

17.00 The management of Elderly BC patients

Chairs: *Monica Fornier, Chiara Saggia*

- The Unfit Patient - *Laura Biganzoli*
- The Fit Patient - *Etienne Brain*
- Anti-senescence compounds: A nutraceutical approach to healthy aging - *Massimiliano Bonafè*

Discussion

17.50 End of Friday's scientific session



Sistema Qualità **ISO 9001**
Progettazione e Erogazione ECM

Saturday, 11th September

8.30 Breakfast Meeting NO CME

- Focus on Eribulin

Chair: *Alessandra Gennari, Filippo Montemurro*

9.00 Triple Negative Breast Cancer: from biology to therapy

Chairs: *Michael Gnant, Javier Cortes*

- **Lecture:** New treatment paradigm “old” targets and game changers - *Giuseppe Curigliano*

- Germline testing beyond BRCA: Do we need it? - *Rachel Wuerlestein*

- Fertility issues in BRCA-mutated young patients - *Matteo Lambertini*

Discussion

9.50 UPO Alumni Award Women in Academy and Research

Chair: *Marco Krengli*

Introduction *Francesca Boccafoschi, Alessandra Gennari*

Recipient *Nadia Harbeck, GianCarlo Avanzi*

Lecture: Academic Research, Education and Patient Care

10.30 Coffee Break

10.50 Metastatic Breast Cancer: new targets & old drugs

Chairs: *Lucia Del Mastro, Serena Di Cosimo*

- CDK 4/6 inhibitors: is there a take home message for daily practice? - *Evandro de Azambuja*

- CDK 4/6 inhibitors: predictive biomarkers - *Grazia Arpino*

- New anti-HER2 and older agents: which sequence? - *Barbara Pistilli*

- Can imaging help tailor HER2-directed therapy? - *Carolien Schroder*

- Is there still a role for chemotherapy? - *Alessandra Fabi*

Discussion

12.00 Chairs: *Giorgio Minotti, Pierluigi Canonico*

Lecture: Regulatory procedures for drug approval in Italy and EU - *Armando Genazzani*



Sistema Qualità **ISO 9001**
Progettazione e Erogazione ECM

12.40 13.45 Test genomici per la valutazione del rischio: un diritto per la scelta di cura?

Chairs: Mario Airoidi, ROP TBD

- Clinical evidence and scientific data - *Fulvia Pedani*
- Patient advocacy and decision making process - *Rosanna D'Antona*
- Tuscany experience: from science to clinical practice - *Pinuccia Musumeci*

Round Table - Discussion

13.45 Closing of the 3rd IBC Meeting 2021

Razionale scientifico

Il carcinoma della mammella rappresenta la neoplasia più frequente nella popolazione femminile a livello mondiale.

Negli ultimi anni abbiamo assistito all'introduzione di nuove terapie e di farmaci biologici che hanno permesso un netto miglioramento della prognosi delle pazienti sia in fase adiuvante che in fase di malattia metastatica. Obiettivo del convegno è un incontro tra gli esperti mondiali del carcinoma della mammella per fare il punto sulle principali innovazioni diagnostiche e terapeutiche nell'ottica dell'ottimizzazione e personalizzazione della terapia.

Il convegno è rivolto a 100 Medici Chirurghi specialisti in:

Oncologia, Medicina Interna, Radiodiagnostica, Radioterapia, Anatomia Patologica, Chirurgia Generale, Chirurgia Plastica e Ricostruttiva, Ginecologia e Ostetricia, Ematologia

ACRONIMI:

- HER2** Human Recettore 2 per il fattore di crescita epidermico umano
- HER2** Human Recettore 2 per il fattore di crescita epidermico umano negativo
- ER** recettore estrogenico
- ER+** recettore estrogenico positivo
- PI3K** fosfoinositide 3-chinasi
- BRCA** Breast Related Cancer Antigens
- CDK 4/6** chinasi ciclina-dipendente
- RT** Radioterapia
- EBC** Early Breast Cancer
- PD-L1** Programmed Death-Ligand 1
- RNA** Acido ribonucleico



Sistema Qualità **ISO 9001**
Progettazione e Erogazione ECM